ClinicalTrials.gg
RecruitingNCT06487403HN-Bio 02Updated Nov 2, 2026

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

An interventional study of Standard of care external beam radiotherapy (single integrated boost) and Standard of care external beam radiotherapy (two-phase treatment) in Squamous Cell Carcinoma of Head and Neck, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 2, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto — 6 open to participants now, 8 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · University Health Network, Toronto.

Planned enrollment
6th of 17
40 · median 30
Started
2025
the only one that year
No phase
8 of 21
3 open now
Registered
19th of 21
by date

Among the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 19th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single centre prospective exploratory study of effects of delayed radiation therapy on adaptive immune response in patients with newly diagnosed (head and neck squamous cell carcinoma) HNSCC receiving curative radiotherapy. This research is part 2 of the HN-BIO study.

Read the detailed description

This study will recruit up to 40 patients planned to receive curative (chemo) radiotherapy for (head and neck squamous cell carcinoma) HNSCC with primary tumor and/or involved lymph node suitable for repeat biopsy in clinic. After being informed about the study and potential risks, patients giving written informed consent will be randomized to receive conventional radiotherapy (single integrated boost or conventional two-phase at clinician discretion) or reversed two-phase treatment with delayed irradiation of elective nodal volumes. Patients will not be informed of their randomization result.

Patients in both arms will undergo a baseline functional magnetic resonance imaging (fMRI) scan, , and within 72 hours, when possible, a biopsy of the primary tumor +/- lymph node will be performed in an out-patient clinic. If a suitable biopsy has been recently performed as part of diagnostic work up the baseline biopsy on study will be omitted when possible. In week 2 of radiotherapy, patients will have a second fMRI scan and a paired biopsy within 72 hours of the scan, where possible. A further optional biopsy and paired fMRI scan in week 4 will be considered for patients who are tolerating therapy without >G1 toxicities. 16-24 hours prior to each biopsy the patient will take oral pimonidazole. At the time of each biopsy and six weeks post completion of radiotherapy a blood draw will be performed to assess lymphocyte preservation and evidence of differential immune activation.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years
  • proven Head and Neck Squamous Cell carcinoma
  • Primary or nodal disease > 3cm for biomarker imaging
  • (ECOG) Performance Status 0-2
  • Planned for curative surgery or (chemo)radiotherapy
  • Willingness to undergo repeat MRI imaging
  • Able to receive and understand verbal and written information regarding study and able to -give written
  • Adequate renal function: Calculated >/= 30ml/min
  • Be able to lie comfortably on back for 1 hour

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another study that requires standard of care radiotherapy
  • More than one contralateral nodal level requiring treatment in phase I
  • As judged by investigator evidence of systemic disease that makes unsuitable for study
  • As judged by investigator, it is deemed unsafe or medically inadvisable to conduct repeat
  • for serial MRI scans
  • Previous solid tumor treated within last 5 years that investigator feels makes unsuitable for study
  • Pregnancy
  • History of gadolinium contrast allergy
  • Non-reversible clotting abnormality
  • History of significant respiratory disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Integrated Boost Radiotherapy

    Standard of care external beam radiotherapy 70Gy in 35 fractions to head and neck tumour and 56 Gy in 35 fraction to elective nodal regions. This will be given as a single integrated boost or two-phase treatment at clinician discretion. For patients with HPV-positive oropharyngeal carcinoma, the treating clinician may alternatively elect to deliver the elective dose as 40 Gy in 20 fractions over the first four weeks of treatment (conventional two-phase approach), consistent with institutional standard of care for this disease.

    Radiation: Standard of care external beam radiotherapy (single integrated boost)

  • Active comparator
    Arm 2: Two Phase Radiotherapy

    Standard of care external beam radiotherapy 70 Gy in 35 fractions to head and neck with delayed 40 Gy in 20 fractions (HPV-positive oropharynx) or 50 Gy in 25 fractions (all other disease) to elective nodal regions. This will be given as reversed two-phase treatment.

    Radiation: Standard of care external beam radiotherapy (two-phase treatment)

Interventions

  • RadiationStandard of care external beam radiotherapy (single integrated boost)

    70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.

  • RadiationStandard of care external beam radiotherapy (two-phase treatment)

    70Gy in 35 fractions, delayed 40 Gy in 20 fractions or 50 Gy in 25 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.

06

What researchers measure

Primary outcomes

  1. Confirm feasibility of recruitment of HN patients for on treatment repeat biopsy of the primary tumor +/- neck nodes

    Achieve a minimum recruitment rate of one patient per month.

    Time frame: 6 weeks

  2. Change in fMRI during radiotherapy

    Study association of changes in fMRI and tissue biomarkers during radiotherapy. Assessed through hypoxic regions visible on imaging scans.

    Time frame: 6 weeks

  3. Assess changes in tumor microenvironment during differing radiotherapy scheduling via repeat biopsy.

    Assess effect of varying radiotherapy treatment volumes on changes in tumor microenvironment via repeat biopsy before and during radiotherapy. Quantify effect of delayed treatment of dLN on dynamic changes tumor immune micro-environment and hypoxia status during radiotherapy. Perform exploratory analysis of study data correlating changes in tumor microenvironment and hypoxia status with disease response to therapy.

    Time frame: 6 weeks

Secondary outcomes

  1. Validate novel and established fMRI imaging as predictive and prognostic radiotherapy biomarkers for HNSCC

    Correlate changes in TME and hypoxia with changes in fMRI on repeat assessment. Correlate fMRI characterized tumor with pathological post-operative specimen.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2028, 39 months after the start.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 39 months is below that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 5, 2024
StartActual
Apr 17, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited, 4 added
What changed in the criteria
Exclusion criteria
  • AddedCurrently participating in another study that requires standard of care radiotherapy
  • AddedMore than one contralateral nodal level requiring treatment in phase I
  • AddedAs judged by investigator, it is deemed unsafe or medically inadvisable to conduct repeat biopsies
  • EditedPrevious solid tumor treated within last 5 years that investigator feels makes unsuitable for study
  • AddedHistory of significant respiratory disease
Nov 2, 2026
Primary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameConfirm feasibility of recruitment of HN patients for on treatment repeat biopsy of the primary tumor +/- neck nodes7 weeks → 6 weeks
  • Time frameChange in fMRI during radiotherapy7 weeks → 6 weeks
  • Time frameAssess changes in tumor microenvironment during differing radiotherapy scheduling via repeat biopsy.7 weeks → 6 weeks
Nov 2, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameValidate novel and established fMRI imaging as predictive and prognostic radiotherapy biomarkers for HNSCC7 weeks → 6 weeks
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Eligibility 1 exclusion criterion edited, 4 added
    What changed in the criteria
    Exclusion criteria
    • AddedCurrently participating in another study that requires standard of care radiotherapy
    • AddedMore than one contralateral nodal level requiring treatment in phase I
    • AddedAs judged by investigator, it is deemed unsafe or medically inadvisable to conduct repeat biopsies
    • EditedPrevious solid tumor treated within last 5 years that investigator feels makes unsuitable for study
    • AddedHistory of significant respiratory disease
    Primary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameConfirm feasibility of recruitment of HN patients for on treatment repeat biopsy of the primary tumor +/- neck nodes7 weeks → 6 weeks
    • Time frameChange in fMRI during radiotherapy7 weeks → 6 weeks
    • Time frameAssess changes in tumor microenvironment during differing radiotherapy scheduling via repeat biopsy.7 weeks → 6 weeks
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameValidate novel and established fMRI imaging as predictive and prognostic radiotherapy biomarkers for HNSCC7 weeks → 6 weeks
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06487403
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Apr 17, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Andrew McPartlin, MD
Contact
andrew.mcpartlin@rmp.uhn.ca
416-946-2132

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion